准MGLL:现在osin调节糖脂代谢以减轻内皮细胞衰老的作用
Jie Huang1, Jinhua Yan1, Zixin Wan1
1Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Journal of lipid research
|September 19, 2025
概括
现在素 (TZ) 通过抑制单甘油脂酶 (MGLL) 来保护血管内皮衰老. 这减少了棕酸的积累,改善了血管功能,并为与年龄有关的血管疾病提供了潜在的治疗方法.
科学领域:
- 心血管生物学 心血管生物学
- 代谢障碍 代谢障碍 代谢障碍
- 细胞衰老 细胞衰老
背景情况:
- 内皮细胞衰老通过损害血管功能,有助于心血管疾病 (CVD) 的发病.
- 内皮衰老和血管衰老的分子机制尚未完全理解,这阻碍了治疗的发展.
研究的目的:
- 调查现在素 (TZ) 对血管内皮衰老的保护作用.
- 阐明TZ对内皮衰老和血管衰老的作用背后的分子机制.
主要方法:
- 使用老老小鼠的体内研究和在人静脉内皮细胞的体内研究.
- 与衰老相关的β-galactosidase染色,脂管学和分子对接模拟.
- 评估血管扩张,血管硬,衰老标志物和特定的脂质代谢物.
主要成果:
- 在老年小鼠中,TZ治疗改善了血管扩张,减少了血管硬性,减弱了衰老标志物.
- 利皮多米克在经过TZ治疗的衰老性内皮细胞中发现了减少的棕酸 (PA) 积累.
- 单甘油脂酶 (MGLL) 在衰老细胞中被上调;TZ直接抑制了MGLL活性,减轻了PA驱动的衰老.
结论:
- 单甘油脂酶 (MGLL) 是内皮衰老的一个新型代谢驱动因素.
- 现在 (TZ) 通过抑制MGLL和减少棕酸积累来缓解内皮老化.
- TZ显示出作为治疗年龄相关血管疾病的治疗剂的潜力.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K

